Persistent therapeutic effect of repeated injections of Onabotulinum toxin A in refractory Bladder Pain Syndrome / Interstitial Cystitis

• Tipo: Resumo de Comunicação em Conferência Internacional
• Data: 2011

Autores

Rui Pinto (Autor) FMUP; Tiago Lopes (Autor) FMUP; Joao Silva (Autor) FMUP; Carlos Silva (Autor) FMUP; Francisco Cruz (Autor) FMUP; Paulo Dinis (Autor) FMUP

Ata de Conferência Internacional

Título: The Journal of Urology

Páginas: 379-379

Persistent therapeutic effect of repeated injections of Onabotulinum toxin A in refractory Bladder Pain Syndrome / Interstitial Cysytitis

Washington DC - USA, 14 a 19 de Maio de 2011

Indexação

Pubmed / Medline

Classificação Científica

FOS: Ciências médicas e da saúde > Medicina clínica

CORDIS: Ciências da Saúde > Ciências Médicas > Medicina > Urologia

Outras Informações

Abstract (EN): INTRODUCTION AND OBJECTIVES: To evaluate the persistence of the therapeutic effect of repeated intra-trigonal injection of Onabotulinum toxin A in patients with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) refractory to first line treatment. METHODS: Fourteen women with BPS/IC refractory to first line treatment received 4 consecutive intra-trigonal injections of Onabotulinum toxin A. Patients were treated under general anaesthesia. With a rigid cystoscope, 100 U of Onabotulinum toxin A were injected in 10 trigonal sites, each receiving 10 U in 1 ml of saline. All patients were discharged under prophylactic antibiotic. The therapeutic effect was evaluated by a 3-day voiding chart, O’Leary-Sant Score (OSS), QoL from IPSS, and by pain visual analogue scale (0 –10) before treatment and every 3 months after each injection. Voiding dysfunction and urinary tract infections (UTIs) were accessed every 3 months. Duration of each injection was determined by the moment patients requested another treatment. RESULTS: Patients had a mean age of 42 y, and a BPS/IC ESSIC classification of 2a (1), 2b (1), 2c (4), 3a (1), 3b (2) and 3c (5). Mean values at baseline were: pain score, 5.91.8; urinary frequency, 16.45.3; OSS, 28.86.3; and QoL, 50.9. All patients reported subjective improvement following each injection. Decreases in pain score, urinary frequency, OSS and QoL after each treatment are shown in Table 1. Each treatment provided symptomatic relief for a period between 9 –10 months. No cases of voiding dysfunction were reported and 5 patients had UTIs after Onabotulinum toxin A injection (2 after 2nd treatment, 1 after 3rd treatment and 2 after 4th treatment). CONCLUSIONS: This study suggests that intra-trigonal injection of 100 U of Onabotulinum toxin A is safe, effective and has maintained effect after repeated injections in refractory BPS/IC. Mean duration of the symptomatic improvement was superior to 9 months after treatment.

Idioma: Inglês

Tipo (Avaliação Docente): Científica